{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:23:17Z","timestamp":1785712997479,"version":"3.56.0"},"reference-count":144,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Learning Objectives<\/jats:title><jats:p>After completing this course, the reader will be able to:<\/jats:p><jats:p>Explain the side effects of hormonal ablation therapy for prostate cancer. Provide a list of potential non-hormonal therapies for treatment of vasomotor symptoms. Appreciate the impact of hormonal ablation therapy on bone mineral density.<\/jats:p><jats:p>Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com<\/jats:p><jats:p>Andropause, or the age-related decline in serum testosterone, has become a popular topic in the medical literature over the past several years. Andropause includes a constellation of symptoms related to lack of androgens, including diminished libido, decreased generalized feeling of well-being, osteoporosis, and a host of other symptoms. The andropause syndrome is very prominent in men undergoing hormonal ablation therapy for prostate cancer. Most significant in this population are the side effects of hot flashes, anemia, gynecomastia, depression, cognitive decline, sarcopenia, a decreased overall quality of life, sexual dysfunction, and osteoporosis with subsequent bone fractures. The concept of andropause in prostate cancer patients is poorly represented in the literature. In this article, we review the current literature on the symptoms, signs, and possible therapies available to men who cannot take replacement testosterone.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.8-5-474","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"474-487","source":"Crossref","is-referenced-by-count":67,"title":["Andropause: Symptom Management for Prostate Cancer Patients Treated With Hormonal Ablation"],"prefix":"10.1093","volume":"8","author":[{"given":"Carrie A.","family":"Thompson","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tait D.","family":"Shanafelt","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"2021122209452350000_R1","doi-asserted-by":"crossref","first-page":"M76","DOI":"10.1093\/gerona\/57.2.M76","article-title":"Andropause: clinical implications of the decline in serum testosterone levels with aging in men","volume":"57","author":"Matsumoto","year":"2002","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2021122209452350000_R2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/1097-0045(2000)45:10+<2::AID-PROS2>3.0.CO;2-Y","article-title":"The male climacterium: clinical signs and symptoms of a changing endocrine environment","volume":"10","author":"Beld","year":"2000","journal-title":"Prostate Suppl"},{"key":"2021122209452350000_R3","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1073\/pnas.94.14.7537","article-title":"Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone","volume":"94","author":"Morley","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122209452350000_R4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/jcem-73-2-221","article-title":"Clinical review 24: androgens in the aging male","volume":"73","author":"Vermeulen","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/oxfordjournals.aje.a009519","article-title":"Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men","volume":"147","author":"Ferrini","year":"1998","journal-title":"Am J Epidemiol"},{"key":"2021122209452350000_R6","first-page":"1002","article-title":"Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men","volume":"75","author":"Orentreich","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1532-5415.1985.tb04195.x","article-title":"Growth hormone, body composition, and aging","volume":"33","author":"Rudman","year":"1985","journal-title":"J Am Geriatr Soc"},{"key":"2021122209452350000_R8","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/meta.2000.8625","article-title":"Validation of a screening questionnaire for androgen deficiency in aging males","volume":"49","author":"Morley","year":"2000","journal-title":"Metabolism"},{"key":"2021122209452350000_R9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-5122(00)00192-4","article-title":"Androgens and aging","volume":"38","author":"Morley","year":"2001","journal-title":"Maturitas"},{"key":"2021122209452350000_R10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199007053230101","article-title":"Effects of human growth hormone in men over 60 years old","volume":"323","author":"Rudman","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R11","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.288.18.2282","article-title":"Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial","volume":"288","author":"Blackman","year":"2002","journal-title":"JAMA"},{"key":"2021122209452350000_R12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"2021122209452350000_R13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3322\/canjclin.52.1.23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"2021122209452350000_R14","volume-title":"Prostate Cancer Trends 1973\u20131995, SEER Program. NIH Pub. No. 99-4543","author":"Stanford","year":"1999"},{"key":"2021122209452350000_R15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/107327480200900406","article-title":"Controversies surrounding androgen deprivation for prostate cancer","volume":"9","author":"Patterson","year":"2002","journal-title":"Cancer Control"},{"key":"2021122209452350000_R16","first-page":"293","article-title":"Studies on prostate cancer. I. The effects of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"2021122209452350000_R17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"2021122209452350000_R18","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0022-5347(17)71004-X","article-title":"Studies on prostate cancer. III. The effects of fever, of desoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate","volume":"46","author":"Huggins","year":"1941","journal-title":"J Urol"},{"key":"2021122209452350000_R19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials","volume":"355","author":"Prostate Cancer Trialists' Collaborative Group","year":"2000","journal-title":"Lancet"},{"key":"2021122209452350000_R20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0090-4295(89)90385-3","article-title":"Flushing: long-term side effect of orchiectomy in treatment of prostatic carcinoma","volume":"33","author":"Charig","year":"1989","journal-title":"Urology"},{"key":"2021122209452350000_R21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00007611-199809000-00010","article-title":"Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer","volume":"91","author":"Schow","year":"1998","journal-title":"South Med J"},{"key":"2021122209452350000_R22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"J Urol"},{"key":"2021122209452350000_R23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/77.11.1207","article-title":"Pathophysiology and treatment of hot flashes","volume":"77","author":"Shanafelt","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2021122209452350000_R24","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","article-title":"Methodologic lessons learned from hot flash studies","volume":"19","author":"Sloan","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209452350000_R25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-5347(17)40081-4","article-title":"Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine","volume":"143","author":"Parra","year":"1990","journal-title":"J Urol"},{"key":"2021122209452350000_R26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-5347(17)35034-6","article-title":"Transdermal clonidine for ameliorating post-orchiectomy hot flashes","volume":"151","author":"Loprinzi","year":"1994","journal-title":"J Urol"},{"key":"2021122209452350000_R27","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0140-6736(83)91092-9","article-title":"Cyproterone acetate in treatment of post-orchiectomy hot flushes. Double-blind cross-over trial","volume":"2","author":"Eaton","year":"1983","journal-title":"Lancet"},{"key":"2021122209452350000_R28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-5347(17)32835-5","article-title":"A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate","volume":"152","author":"Smith","year":"1994","journal-title":"J Urol"},{"key":"2021122209452350000_R29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0090-4295(92)90401-H","article-title":"Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer","volume":"40","author":"Miller","year":"1992","journal-title":"Urology"},{"key":"2021122209452350000_R30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0090-4295(92)90264-W","article-title":"Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone","volume":"39","author":"Atala","year":"1992","journal-title":"Urology"},{"key":"2021122209452350000_R31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0090-4295(99)00370-2","article-title":"Transdermal estrogen in the treatment of hot flushes in men with prostate cancer","volume":"55","author":"Gerber","year":"2000","journal-title":"Urology"},{"key":"2021122209452350000_R32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/bmj.293.6544.413","article-title":"Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects","volume":"293","author":"Henriksson","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2021122209452350000_R33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R34","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1789::AID-CNCR27>3.0.CO;2-#","article-title":"Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes","volume":"82","author":"Quella","year":"1998","journal-title":"Cancer"},{"key":"2021122209452350000_R35","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/S0022-5347(01)67365-8","article-title":"Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome","volume":"153","author":"Dawson","year":"1995","journal-title":"J Urol"},{"key":"2021122209452350000_R36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0025-6196(11)63364-8","article-title":"Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer","volume":"72","author":"Wehbe","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"2021122209452350000_R37","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1200\/JCO.1999.17.3.1086a","article-title":"Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate","volume":"17","author":"Burch","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122209452350000_R38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005392-199907000-00024","article-title":"Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer","volume":"162","author":"Quella","year":"1999","journal-title":"J Urol"},{"key":"2021122209452350000_R39","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"2021122209452350000_R40","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","article-title":"Phase III evaluation of fluoxetine for treatment of hot flashes","volume":"20","author":"Loprinzi","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209452350000_R41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/A:1008382706068","article-title":"A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors","volume":"11","author":"Stearns","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122209452350000_R42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1099-1611(199803\/04)7:2<129::AID-PON294>3.0.CO;2-T","article-title":"Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer","volume":"7","author":"Roth","year":"1998","journal-title":"Psychooncology"},{"key":"2021122209452350000_R43","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.54.11.2161","article-title":"Gabapentin's effects on hot flashes and hypothermia","volume":"54","author":"Guttuso","year":"2000","journal-title":"Neurology"},{"key":"2021122209452350000_R44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1345\/aph.1A139","article-title":"Gabapentin for hot flashes in prostate cancer","volume":"36","author":"Jeffery","year":"2002","journal-title":"Ann Pharmacother"},{"key":"2021122209452350000_R45","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.4065\/77.11.1159","article-title":"Pilot evaluation of gabapentin for treating hot flashes","volume":"77","author":"Loprinzi","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2021122209452350000_R46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-5347(01)61789-0","article-title":"Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study","volume":"161","author":"Hammar","year":"1999","journal-title":"J Urol"},{"key":"2021122209452350000_R47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0090-4295(96)00381-0","article-title":"Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study","volume":"48","author":"Higano","year":"1996","journal-title":"Urology"},{"key":"2021122209452350000_R48","first-page":"1069","article-title":"Impact of intermittent androgen deprivation on quality of life (QOL)","volume":"155","author":"Bales","year":"1996","journal-title":"Proc Am Urol Assoc"},{"key":"2021122209452350000_R49","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"2021122209452350000_R50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5694\/j.1326-5377.1997.tb126646.x","article-title":"Hip fracture in elderly men: prognostic factors and outcomes","volume":"167","author":"Diamond","year":"1997","journal-title":"Med J Aust"},{"key":"2021122209452350000_R51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2021122209452350000_R52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.2001.81.1.419","article-title":"Sex steroids and bone","volume":"81","author":"Compston","year":"2001","journal-title":"Physiol Rev"},{"key":"2021122209452350000_R53","first-page":"3626","article-title":"Hormonal and biochemical parameters in the determination of osteoporosis in elderly men","volume":"84","author":"Center","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","article-title":"Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man","volume":"331","author":"Smith","year":"1994","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R55","first-page":"3689","article-title":"Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens","volume":"80","author":"Morishima","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJM199808273390905","article-title":"Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency","volume":"339","author":"Bilezikian","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199707103370204","article-title":"Effect of testosterone and estradiol in a man with aromatase deficiency","volume":"337","author":"Carani","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R58","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1359\/jbmr.1997.12.11.1833","article-title":"Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study","volume":"12","author":"Greendale","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2021122209452350000_R59","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1172\/JCI10942","article-title":"Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men","volume":"106","author":"Falahati-Nini","year":"2000","journal-title":"J Clin Invest"},{"key":"2021122209452350000_R60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","article-title":"Osteoporosis after orchiectomy for prostate cancer","volume":"157","author":"Daniell","year":"1997","journal-title":"J Urol"},{"key":"2021122209452350000_R61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<545::AID-CNCR17>3.0.CO;2-3","article-title":"Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma","volume":"79","author":"Townsend","year":"1997","journal-title":"Cancer"},{"key":"2021122209452350000_R62","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/S0022-5347(05)65661-3","article-title":"Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer","volume":"166","author":"Oefelein","year":"2001","journal-title":"J Urol"},{"key":"2021122209452350000_R63","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1464-410X.2000.00774.x","article-title":"Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer","volume":"86","author":"Hatano","year":"2000","journal-title":"BJU Int"},{"key":"2021122209452350000_R64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(00)00895-5","article-title":"Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer","volume":"57","author":"Kiratli","year":"2001","journal-title":"Urology"},{"key":"2021122209452350000_R65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-5347(05)68000-7","article-title":"Progressive osteoporosis during androgen deprivation therapy for prostate cancer","volume":"163","author":"Daniell","year":"2000","journal-title":"J Urol"},{"key":"2021122209452350000_R66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(99)00301-5","article-title":"Androgen deprivation therapy for prostate cancer results in significant loss of bone density","volume":"54","author":"Wei","year":"1999","journal-title":"Urology"},{"key":"2021122209452350000_R67","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R68","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","article-title":"Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma","volume":"161","author":"Maillefert","year":"1999","journal-title":"J Urol"},{"key":"2021122209452350000_R69","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R70","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1561::AID-CNCR11>3.0.CO;2-Z","article-title":"The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy","volume":"83","author":"Diamond","year":"1998","journal-title":"Cancer"},{"key":"2021122209452350000_R71","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone-na\u00efve men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"key":"2021122209452350000_R72","first-page":"314A","article-title":"Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression","volume":"18","author":"Higano","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209452350000_R73","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone therapy on bone mineral density in hypogonadal men","volume":"82","author":"Behre","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R74","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R75","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.1210\/jcem.86.11.7988","article-title":"Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study","volume":"86","author":"Ringe","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R76","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R77","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M","article-title":"The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study","volume":"92","author":"Diamond","year":"2001","journal-title":"Cancer"},{"key":"2021122209452350000_R78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostate cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2021122209452350000_R79","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1210\/jc.2002-020539","article-title":"The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer","volume":"87","author":"Taxel","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 1","key":"2021122209452350000_R80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-4295(02)01579-0","article-title":"Osteoporosis during androgen deprivation therapy for prostate cancer","volume":"60","author":"Smith","year":"2002","journal-title":"Urology"},{"issue":"suppl 1","key":"2021122209452350000_R81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0090-4295(01)01251-1","article-title":"Osteoporosis due to androgen deprivation therapy in men with prostate cancer","volume":"58","author":"Daniell","year":"2001","journal-title":"Urology"},{"key":"2021122209452350000_R82","first-page":"257","article-title":"The role of testicular secretions as indicated by the effects of castration in man and by studies of pathological conditions and the short lifespan associated with maleness","volume":"3","author":"Hamilton","year":"1948","journal-title":"Recent Prog Horm Res"},{"key":"2021122209452350000_R83","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/j.1552-4604.1974.tb02298.x","article-title":"Androgens and erythropoiesis","volume":"14","author":"Evens","year":"1974","journal-title":"J Clin Pharmacol"},{"key":"2021122209452350000_R84","first-page":"442","article-title":"Erythropoietic mechanism of androgens: a critical review and clinical implications","volume":"67","author":"Molinari","year":"1982","journal-title":"Haematologica"},{"key":"2021122209452350000_R85","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJM197307122890205","article-title":"Androgens and erythropoiesis","volume":"289","author":"Shahidi","year":"1973","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2","article-title":"Anemia after orchiectomy","volume":"59","author":"Fonseca","year":"1998","journal-title":"Am J Hematol"},{"key":"2021122209452350000_R87","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ajh.2830360306","article-title":"Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men","volume":"36","author":"Weber","year":"1991","journal-title":"Am J Hematol"},{"key":"2021122209452350000_R88","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","article-title":"Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade","volume":"79","author":"Strum","year":"1997","journal-title":"Br J Urol"},{"key":"2021122209452350000_R89","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<243::AID-PROS5>3.0.CO;2-C","article-title":"Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy","volume":"29","author":"Asbell","year":"1996","journal-title":"Prostate"},{"key":"2021122209452350000_R90","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209452350000_R91","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/(SICI)1097-0045(19970515)31:3<153::AID-PROS2>3.0.CO;2-M","article-title":"Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin","volume":"31","author":"Beshara","year":"1997","journal-title":"Prostate"},{"key":"2021122209452350000_R92","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/003655901750425864","article-title":"Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer\u2014a randomized study","volume":"35","author":"Johansson","year":"2001","journal-title":"Scand J Urol Nephrol"},{"key":"2021122209452350000_R93","first-page":"356a","article-title":"Weekly erythropoietin for patients with chemotherapy induced anemia: a randomized, placebo-controlled trial in the North Central Cancer Treatment Group","volume":"21","author":"Silberstein","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209452350000_R94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0047-6374(98)00130-4","article-title":"Predictors of skeletal muscle mass in elderly men and women","volume":"107","author":"Baumgartner","year":"1999","journal-title":"Mech Ageing Dev"},{"key":"2021122209452350000_R95","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1067\/mlc.2001.113504","article-title":"Sarcopenia","volume":"137","author":"Morley","year":"2001","journal-title":"J Lab Clin Med"},{"key":"2021122209452350000_R96","first-page":"3469","article-title":"Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men\u2014a clinical research center study","volume":"81","author":"Brodsky","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R97","first-page":"2647","article-title":"Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age","volume":"84","author":"Snyder","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0378-5122(03)00083-5","article-title":"An integrative review on current evidence of testosterone replacement therapy for the andropause","volume":"45","author":"Tan","year":"2003","journal-title":"Maturitas"},{"key":"2021122209452350000_R99","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0959-8049(00)00084-8","article-title":"Fatigue in patients with prostate cancer receiving hormone therapy","volume":"36","author":"Stone","year":"2000","journal-title":"Eur J Cancer"},{"key":"2021122209452350000_R100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0022-5347(05)68001-9","article-title":"Treatment of vitamin D deficiency in patients with metastatic prostate cancer may improve bone pain and muscle strength","volume":"163","author":"Veldhuizen","year":"2000","journal-title":"J Urol"},{"key":"2021122209452350000_R101","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0090-4295(00)00823-2","article-title":"Gynecomastia in patients with prostate cancer: a review of treatment options","volume":"56","author":"McLeod","year":"2000","journal-title":"Urology"},{"key":"2021122209452350000_R102","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0045(2000)45:10+<32::AID-PROS7>3.0.CO;2-V","article-title":"Side effects of endocrine treatment and their mechanisms: castration, antiandrogens, and estrogens","volume":"10","author":"Hedlund","year":"2000","journal-title":"Prostate Suppl"},{"key":"2021122209452350000_R103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/00365596909135402","article-title":"Prevention of gynecomastia by local roentgen irradiation in estrogen-treated prostatic carcinoma","volume":"3","author":"Alfthan","year":"1969","journal-title":"Scand J Urol Nephrol"},{"key":"2021122209452350000_R104","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0022-5347(17)56713-0","article-title":"Pre-estrogen breast irradiation for patients with carcinoma of the prostate: a critical review","volume":"121","author":"Gagnon","year":"1979","journal-title":"J Urol"},{"key":"2021122209452350000_R105","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-5347(17)61097-8","article-title":"Bilateral mastectomy and irradiation in the prevention of estrogen induced gynecomastia","volume":"107","author":"Srinivasan","year":"1972","journal-title":"J Urol"},{"key":"2021122209452350000_R106","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0022-5347(17)64983-8","article-title":"Subareolar mastectomy to prevent estrogen-induced male breast enlargement: a new procedure for use in patients with carcinoma of the prostate","volume":"87","author":"Amelar","year":"1962","journal-title":"J Urol"},{"key":"2021122209452350000_R107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00007256-199010050-00003","article-title":"Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review","volume":"10","author":"Bahrke","year":"1990","journal-title":"Sports Med"},{"key":"2021122209452350000_R108","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0447.1988.tb05132.x","article-title":"Total and free testosterone in depressed men","volume":"77","author":"Levitt","year":"1988","journal-title":"Acta Psychiatr Scand"},{"key":"2021122209452350000_R109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1192\/bjp.161.5.629","article-title":"Salivary testosterone levels and major depressive illness in men","volume":"161","author":"Davies","year":"1992","journal-title":"Br J Psychiatry"},{"key":"2021122209452350000_R110","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1210\/jcem.82.6.3988","article-title":"Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial","volume":"82","author":"Sih","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0006-3223(85)90088-5","article-title":"Plasma testosterone levels, depression, sexuality, and age","volume":"20","author":"Yesavage","year":"1985","journal-title":"Biol Psychiatry"},{"key":"2021122209452350000_R112","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1210\/jcem.84.2.5495","article-title":"Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study","volume":"84","author":"Barrett-Connor","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/j.1939-4640.1992.tb00319.x","article-title":"A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men","volume":"13","author":"Burris","year":"1992","journal-title":"J Androl"},{"key":"2021122209452350000_R114","first-page":"3578","article-title":"Testosterone replacement therapy improves mood in hypogonadal men\u2014a clinical research center study","volume":"81","author":"Wang","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0165-0327(97)00168-7","article-title":"Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression","volume":"48","author":"Seidman","year":"1998","journal-title":"J Affect Disord"},{"key":"2021122209452350000_R116","first-page":"317","article-title":"Depression during hormonal treatment of prostate cancer","volume":"8","author":"Rosenblatt","year":"1995","journal-title":"J Am Board Fam Pract"},{"key":"2021122209452350000_R117","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/gps.391","article-title":"Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease","volume":"16","author":"Almeida","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"2021122209452350000_R118","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing analogues and cyproterone acetate: a randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"BJU Int"},{"key":"2021122209452350000_R119","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1097-0045(19990915)41:1<58::AID-PROS8>3.0.CO;2-3","article-title":"Defining an international research agenda for quality of life in men with prostate cancer","volume":"41","author":"Litwin","year":"1999","journal-title":"Prostate"},{"key":"2021122209452350000_R120","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00000421-199808000-00002","article-title":"Quality-of-life outcomes in long-term survivors of advanced prostate cancer","volume":"21","author":"Litwin","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"2021122209452350000_R121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0959-8049(95)00402-5","article-title":"The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853","volume":"32A","author":"Silva","year":"1996","journal-title":"Eur J Cancer"},{"key":"2021122209452350000_R122","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2001.19.17.3750","article-title":"Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study","volume":"19","author":"Potosky","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209452350000_R123","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/jnci\/90.20.1537","article-title":"Quality of life in advanced prostate cancer: results of a randomized therapeutic trial","volume":"90","author":"Moinpour","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"2021122209452350000_R124","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-4295(96)00485-2","article-title":"Health-related quality of life among patients with metastatic prostate cancer","volume":"49","author":"Albertsen","year":"1997","journal-title":"Urology"},{"issue":"suppl 3","key":"2021122209452350000_R125","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/1097-0142(19930201)71:3+<1143::AID-CNCR2820711437>3.0.CO;2-I","article-title":"A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy","volume":"71","author":"Herr","year":"1993","journal-title":"Cancer"},{"key":"2021122209452350000_R126","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0022-5347(05)67533-7","article-title":"Quality of life of asymptomatic men with monmetastatic prostate cancer on androgen deprivation therapy","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"2021122209452350000_R127","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pon.599","article-title":"Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring","volume":"11","author":"Green","year":"2002","journal-title":"Psychooncology"},{"key":"2021122209452350000_R128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0090-4295(99)80092-2","article-title":"Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report","volume":"45","author":"Goldenberg","year":"1995","journal-title":"Urology"},{"key":"2021122209452350000_R129","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2021122209452350000_R130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"2021122209452350000_R131","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1210\/jcem-70-3-792","article-title":"Testosterone replacement therapy and sleep-related erections in hypogonadal men","volume":"70","author":"Cunningham","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R132","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01542116","article-title":"Changes in erectile responsiveness during androgen replacement therapy","volume":"12","author":"Bancroft","year":"1983","journal-title":"Arch Sex Behav"},{"key":"2021122209452350000_R133","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jcem-57-3-557","article-title":"The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men","volume":"57","author":"Kwan","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122209452350000_R134","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence. NIH Consensus Development Panel on Impotence","volume":"270","author":"NIH Consensus Conference","year":"1993","journal-title":"JAMA"},{"key":"2021122209452350000_R135","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0022-5347(01)65062-6","article-title":"Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes","volume":"157","author":"Morales","year":"1997","journal-title":"J Urol"},{"key":"2021122209452350000_R136","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/PL00007086","article-title":"Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction","volume":"18","author":"Schultheiss","year":"2000","journal-title":"World J Urol"},{"key":"2021122209452350000_R137","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF02600118","article-title":"Testosterone for erectile failure","volume":"8","author":"Mulligan","year":"1993","journal-title":"J Gen Intern Med"},{"key":"2021122209452350000_R138","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1464-410X.1984.tb07166.x","article-title":"Sexual function in prostatic cancer patients treated with radiotherapy, orchiectomy or oestrogens","volume":"56","author":"Bergman","year":"1984","journal-title":"Br J Urol"},{"key":"2021122209452350000_R139","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N","article-title":"Intermittent endocrine therapy for advanced prostate cancer","volume":"58","author":"Klotz","year":"1986","journal-title":"Cancer"},{"key":"2021122209452350000_R140","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122209452350000_R141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1442-2042.1999.06128.x","article-title":"Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy","volume":"6","author":"Marumo","year":"1999","journal-title":"Int J Urol"},{"key":"2021122209452350000_R142","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJM199805143382001","article-title":"Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group","volume":"338","author":"Goldstein","year":"1998","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199701023360101","article-title":"Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group","volume":"336","author":"Padma-Nathan","year":"1997","journal-title":"N Engl J Med"},{"key":"2021122209452350000_R144","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJM199604043341401","article-title":"Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group","volume":"334","author":"Linet","year":"1996","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.8-5-474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.8-5-474","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/474\/41840311\/oncolo_8_5_474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/8\/5\/474\/41840311\/oncolo_8_5_474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T06:55:05Z","timestamp":1705215305000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/8\/5\/474\/6387538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":144,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2003,10,1]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.8-5-474","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,10,1]]},"published":{"date-parts":[[2003,10,1]]}}}